Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
July 22, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
July 21, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
June 09, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
June 02, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
May 10, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
SONN
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
April 13, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 08, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
March 16, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
SONN
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
February 09, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
February 08, 2022
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
December 17, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
August 30, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
August 19, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
August 16, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
SONN
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
June 14, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
June 08, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
SONN
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
May 17, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
May 10, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
SONN
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
May 03, 2021
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Tickers
SONN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.